meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs Standard of Care (SoC)
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
Asian type
cancer location (gastric)
cancer location (gastro-esophageal)
ECOG 0
ECOG 1
Gender, female
Gender, male
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
irORR
irPFS
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
deaths (OS)
mGC or mGEJC - L2 - all population
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
versus Standard of Care (SoC)
Ipilimumab (10 mg/kg) vs. Standard of Care (SoC)
1
certainty unassessable
+54%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open